HIV-Associated Lipodystrophy Treatment Market Analysis & Forecast: 2026-2033
The HIV-Associated Lipodystrophy Treatment Market size is anticipated to grow at a CAGR of 4.0%, from USD 199.2 Mn in 2026 to approximately USD 263.0 Mn by 2033. The market growth is primarily driven by the increasing number of people receiving long-term antiretroviral therapy, rising awareness regarding HIV-associated fat redistribution disorders, growing demand for pharmacological treatments such as tesamorelin, and increasing adoption of cosmetic and reconstructive procedures for managing facial lipoatrophy and abnormal fat accumulation. Improvements in HIV survival rates, greater emphasis on patients’ quality of life, and expanding access to specialized HIV care are also expected to support market growth during the forecast period. According to UNAIDS, approximately 40.8 Mn people were living with HIV globally in 2024, of whom 31.6 Mn were accessing antiretroviral therapy, compared with only 7.7 Mn in 2010.
The rising incidence of weight gain, central adiposity, insulin resistance, and other changes in body composition seen as a result of antiretroviral therapy has created a need for HIV-related lipodystrophy diagnosis and management. Individuals suffering from excessive fat deposition in their abdomen might need treatment with pharmacotherapy, metabolic assessment, dietary modification, or surgery.
A 2024 study of 2,624 patients starting antiretroviral drugs by the AIDS Clinical Trials Group found an average increase of 3.6 kg weight in the first 48 weeks. In the follow-up, 130 subjects got diabetes, 360 had metabolic syndromes, and 424 had a cardiometabolic condition.
HIV-induced fat redistribution is now gaining attention as an aspect of cardiometabolic risk management and not just a cosmetic issue. Visceral adiposity may be accompanied by dyslipidemia, glucose intolerance, high blood pressure, and insulin resistance, thus prompting clinicians to test patients for such conditions more often.
A study conducted in March 2025, which was done prospectively on a group of 449 HIV-infected individuals before initiating their ARTs, revealed that 16.9% of them were suffering from metabolic syndrome. Of them, 49.8% had low levels of HDL cholesterol, 26.1% had high triglyceride levels, 23.1%
|
Current Event |
Description and its Impact |
|
U.S. HHS/NIH Expands HIV Guidelines to Cover Cardiovascular and Metabolic Complications (September 2025) |
|
|
CMS Implements Medicare Part D Out-of-Pocket Cap and Prescription Payment Plan (January–May 2025) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of lipodystrophy type, the lipoaccumulation category is expected to hold the leading position in terms of the HIV-associated lipodystrophy treatment market share, estimated at about 64.0% in 2026. The leadership of the segment is explained by the fact that visceral and central abdominal fat keeps accumulating in those patients who have been taking anti-retroviral therapy for a prolonged period of time.
According to research conducted on the usage of anthropometric measurements and published in the journal AIDS in June 2026, the number of HIV patients with obesity rose from 45%, using the traditional definition, to 78% based on the new definition.
In March 2025, Theratechnologies presented new findings from the Visceral Adiposity Measurement and Observation Study (VAMOS) at the 2025 Conference on Retroviruses and Opportunistic Infections.
To learn more about this report, Request Free Sample
Based on therapeutic type, the anabolism regulators segment is forecast to account for the largest share of HIV lipodystrophy treatment market valued at around 57.5% in 2026. This market segment can be attributed to growth hormone releasing factor agonists, especially Tesamorelin, because of their selective effect on excessive fat deposition in abdomen and lack of directly competing drugs in market.
In July 2025, Theratechnologies announced its highest-ever number of patients being enrolled in its EGRIFTA line, reflecting its ongoing popularity of prescribing treatments involving growth hormone-releasing factor. Although there was a temporary shortage of the product, the average selling price of EGRIFTA SV rose by around 5.0% in the second quarter of fiscal 2025. The firm indicated that there was solid demand for EGRIFTA WR and EGRIFTA SV sales.
On the basis of distribution channel, the retail pharmacies segment, including retail specialty pharmacies, is anticipated to account for the largest market share of approximately 52.0% in 2026. The segment’s growth is attributable to the outpatient nature of HIV-associated lipodystrophy treatment, home administration of injectable therapies, recurring prescription fulfilment, insurance verification, prior-authorization support, and direct medicine delivery through specialty-pharmacy networks.
The concentration of specialty-drug fulfilment among major pharmacy benefit managers further supports the segment. The three largest U.S. pharmacy benefit managers, CVS Caremark, Optum Rx, and Express Scripts, collectively control approximately 70% of specialty-drug prescriptions in the United States. This concentrated pharmacy infrastructure allows manufacturers and healthcare providers to manage reimbursement, patient onboarding, refill coordination, and distribution of high-cost medicines through established specialty-retail networks.
In February 2025, Theratechnologies resumed the U.S. distribution of EGRIFTA SV (tesamorelin) after receiving authorization from the U.S. FDA to release two newly manufactured batches, representing up to six months of patient supply. The product was made available for immediate shipment to network pharmacies.
To learn more about this report, Request Free Sample
North America is anticipated to account for approximately 45.0% of the global HIV-associated lipodystrophy treatment market in 2026. The region’s dominance is attributed to its well-established HIV-care infrastructure, high utilization of antiretroviral therapy, access to metabolic and endocrinology specialists, comparatively strong reimbursement coverage, and established availability of targeted specialty treatments for HIV-associated abdominal-fat accumulation.
The U.S. CDC reported 38,793 HIV diagnoses in 2024, demonstrating the continued addition of patients requiring long-term antiretroviral treatment and monitoring for metabolic and body-composition complications. The U.S. South alone accounted for 51% of new diagnoses, supporting sustained demand across major treatment centres and specialty-pharmacy networks.
In September 2025, Michigan-based Future Pak, LLC, through its affiliate CB Biotechnology, completed the acquisition of Theratechnologies, the developer and commercializer of the EGRIFTA tesamorelin franchise for HIV-associated lipodystrophy.
Asia Pacific is anticipated to witness the fastest growth in the HIV-associated lipodystrophy treatment market during 2026–2033. Regional growth is expected to be driven by the large HIV patient population, continued expansion of antiretroviral-treatment coverage, increasing survival among treated patients, transition toward long-term chronic HIV management, and rising recognition of ART-associated weight gain and metabolic complications.
According to UNAIDS, an estimated 6.9 million people had HIV in the Asia Pacific region in 2024, where 69% of these individuals were on antiretroviral therapy. Additionally, there were an estimated 300,000 new cases of HIV in the Asia Pacific region in 2024, which implies that there is a need for continued initiation and monitoring of patients on antiretroviral therapy. The coverage of antiretrovirals is above 90% in Cambodia but still under 50% in some countries.
In April 2025, Galderma announced the commercial launch of Sculptra, its poly-L-lactic acid regenerative biostimulator, in China following approval from the National Medical Products Administration.
The U.S. HIV-Associated Lipodystrophy Treatment Market is expected to maintain a leading position owing to its extensive HIV-care infrastructure, strong public reimbursement and medication-support programs, availability of specialist metabolic care, and growing emphasis on managing chronic complications among people receiving long-term antiretroviral therapy.
In December 2025, the U.S. Health Resources and Services Administration reported that the Ryan White HIV/AIDS Program served 601,853 people in 2024, representing more than 50% of people with diagnosed HIV in the country. Approximately 91.4% of patients receiving medical care through the program achieved viral suppression, while 47.4% of clients were aged 50 years or older.
China is expected to witness strong growth in the HIV-Associated Lipodystrophy Treatment Market over the forecast period. The growth is attributed to expanding antiretroviral-treatment coverage, rapid ART initiation, improving viral suppression, increasing use of modern treatment regimens, and the gradual transition of HIV care from acute infection management toward long-term metabolic and ageing-related care.
China’s national HIV/AIDS Prevention and Control Plan for 2024–2030, announced in December 2024, established targets for more than 95% of diagnosed people with HIV to receive antiretroviral treatment and more than 95% of treated patients to achieve viral suppression. These treatment targets are intended to be maintained and further improved through 2030, creating a larger population receiving continuous, long-duration ART.
Some of the major key players in HIV-Associated Lipodystrophy Treatment Market are Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 199.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.0% | 2033 Value Projection: | USD 263.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
